Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).

Paclitaxel and Bevacizumab Regimen for Metastatic Breast Cancer

“…PB is used to treat metastatic breast cancer ( Table 1 ). 1-10 PB has also been used in other advanced cancers such as ovarian, lung, and melanoma. 11-13…”

“…Cardiovascular: Epistaxis (grade 3 or 4) 1% to 4% 3,6-8,10 ; hypertension (grade 1) 7%, 4 (grade 3) 1% to 17%, 3,8,10,11 (grade 4) 0.5% 3,8 ; thrombus (grade 2) 3% to 4%, 4 (grade 3) 2% to 4%, 3,8 (grade 4) 1% to 4%., 3,7,8…”

“…Renal Function Paclitaxel: No dosage reduction necessary for renal function 19 Bevacizumab Bevacizumab should be held for 2+ or greater on dipstick urine analysis until resolution 2 If 24-hour urine protein collection shows greater than or equal to 2 g protein/24 hours, bevacizumab should be held until urine protein is less than 2 g protein/24 hours 2 In the studies reviewed, bevacizumab was held for grade 2 or 3 proteinuria until resolution. 3-13 …”